Trial · NCT02873559
Effect of PROGRESSive Training and Teststerone in Older Frail Men
NCT02873559, Phase 2, Phase 3, Completed, University Hospital, Gentofte, Copenhagen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of PROGRESSive Training and Teststerone in Older Frail Men. Trials, record NCT02873559. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02873559
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of PROGRESSive Training and Teststerone in Older Frail Men
- NCT number
- NCT02873559
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 192 participants, actual
- Lead sponsor
- University Hospital, Gentofte, Copenhagen
- Conditions
- Muscle Weakness
- Interventions
- testosterone, Progressive muscle training
- First posted
- 2016-08-19
- Last updated
- 2024-05-29
Source ClinicalTrials.gov
Registered outcomes36
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Stand-up-and Sit-test | up to 5 months (at study completion) | It is a measure of overall strength in the lower extremities. Result of the test is defined as the number of times the participant can stand up and sit from a chair in 30 seconds. There is a good correlation (r = 0.78) with a leg press and an acceptable test-retest reliability (ICC = 0.86). |
| Secondary | Frequency and severity of falls via questionaire | At baseline, 1 month, 5 months (at study completion) | included in the monitoring of adverse events. |
| Secondary | Balance ability, | At baseline, 1 month, 5 months (at study completion) | Tandem Test containing three starting positions: 1) Standing with feet together, standing in the semi-tandem position and standing in the tandem stand. coupled with decrease risk of fall. |
| Secondary | Avlund mobility scale | At baseline, 1 month, 5 months (at study completion) | Questions about experiencing fatigue and support needs of ordinary everyday activities. Avlund mobility scale is correlated with the isometric muscle strength, simple function tests , increased risk of hospitalization and mortality |
| Secondary | Leg extensor Power Rig test | At baseline, 1 month, 5 months (at study completion) | An instrument for measuring muscle strength in the lower extremities. |
| Secondary | Isometric muscle strength | At baseline, 1 month, 5 months (at study completion) | Measurement of isometric muscle strength m. quadriceps in a seated leg press. |
| Secondary | Armflexion Test: | At baseline, 1 month, 5 months (at study completion) | Measures of overall strength in the upper extremities. The number of times the participant can inflect the elbow with dumbbell is measured in 30 sec. |
| Secondary | 2-minute knee lift test: | At baseline, 1 month, 5 months (at study completion) | Measures aerobic capacity in the elderly. Number of high knee lifts in 2 minutes. |
| Secondary | 2,45minute up-and-go test: | At baseline, 1 month, 5 months (at study completion) | Target for basic mobility in the elderly. Time it takes to rise from a chair, walk around a cone 2,45m away, go back and sit down again. Moderate to good correlation between the corresponding 3m test and Berg Balance Scale (r = 0.81), walking speed (r = 0.61) and Barthel index (r = 0.78) and a good test-retest- reliability (ICC = 0.98). |
| Secondary | DXA scan | At baseline, 1 month, 5 months (at study completion) | Lean body mass. Measurement of fat and fat-free mass and total bone mass (BMC). Executed only at baseline and at study end. |
1 to 10 of 36Source ClinicalTrials.gov
See all 36 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02873559
GET https://conductscience.org/api/trials/v1/NCT02873559/registered?page=2